Peloquin F, Breton MC, Wasserman M, Wilson M, McDade C, Farkouh R. Pneumococcal vaccination provides substantial value for money for Canadians. Presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.
Wasserman M, Wilson M, McDade C, Grajales AG, Palacios MG, Baez- Revueltas FB, Farkouh R. Estimating the clinical and economic impact of maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico. Presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.
Wasserman M, Rejas J, Mendez C, Wilson M, McDade C, Moffatt M, Farkouh R. Estimating clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) Pneumococcal Conjugate Vaccine in Spain. Presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 24, 2017. Madrid, Spain.
Wasserman M, Wilson M, Breton MC, Peloquin F, McDade C, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent Pneumococcal Conjugate Vaccine (PCV13) to a lower-valent (PCV10) vaccine in Canada. Poster presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 23, 2017. Madrid, Spain.
Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.